How many people qualify for GLP-1 medications worldwide?

TL;DR

A January 2026 Lancet study found roughly 1 in 4 adults worldwide meets the clinical criteria for GLP-1 therapy - yet four-fifths of those eligible live in countries where the drugs are largely out of reach.

GLP-1 medications like Ozempic and Wegovy have reshaped how doctors think about obesity treatment. But until recently nobody had rigorously counted how many people globally might benefit from them. A landmark study published in January 2026 did exactly that - and the numbers are staggering. If you are already on a GLP-1 drug, you are one of a comparatively tiny fraction of the people who could theoretically be prescribed one.

What the Lancet study found

Researchers from Mass General Brigham, Washington University School of Medicine in St. Louis, and Emory University's Rollins School of Public Health analyzed data from 810,635 adults aged 25 to 64 across 99 countries. The data covered the period from 2008 to 2021. They applied the same eligibility criteria used in clinical practice: a BMI above 30, or a BMI above 27 combined with either hypertension or type 2 diabetes.

Their finding: 27% of adults worldwide - roughly 1.5 billion people - meet the criteria for GLP-1 therapy. Published in The Lancet Diabetes and Endocrinology, the paper is now the most comprehensive global estimate of GLP-1 eligibility to date.

Who qualifies - and where they live

The distribution is striking. Some regions have far higher eligibility rates than others:

• Europe and North America: 42.8% of adults qualify
• Pacific Islands: 41.0% qualify
• Women overall: 28.5% eligible, slightly higher than men
• Adults aged 55-64: 38.3% eligible, compared to just 17.9% of those aged 25-34

Age matters a lot. Weight-related conditions accumulate over time, which is why eligibility roughly doubles between young adulthood and middle age. If you are in your 50s and have been told you are borderline for a GLP-1 prescription, the data suggest you are far from alone.

The access gap: four-fifths live where drugs are unavailable

The most uncomfortable finding in the paper is not the overall number. It is where those people live. Four-fifths of the 1.5 billion eligible adults reside in low- and middle-income countries where semaglutide and tirzepatide are either unregistered, unaffordable, or simply unavailable through public health systems.

Lead author Dr. Jennifer Manne-Goehler of Brigham and Women's Hospital described GLP-1 medications as "a potentially transformational and scalable tool for obesity, type 2 diabetes" and related complications. The challenge, she and her co-authors noted, is that transformation requires access - and that access is currently concentrated in wealthy nations.

The World Health Organization has signaled support for including GLP-1 medications on its essential medicines list, which would pressure governments to make them more available. That process is ongoing.

What this means if you are currently on GLP-1 therapy

If you are taking Ozempic, Wegovy, Mounjaro, or Zepbound, you sit in an unusual position. You are among the small percentage of eligible people who actually has access to these drugs. That access comes with its own set of challenges - cost, side effects, nutritional considerations - that most people globally will never have to navigate.

One implication of large-scale GLP-1 use that the researchers did not address, but that clinical data increasingly flags, is the effect these medications have on nutrient absorption. When you eat significantly less over months or years, you take in less of every vitamin and mineral your body needs. Early findings suggest deficiencies in vitamin B12, vitamin D, iron, and magnesium are among the most common consequences of sustained GLP-1 use. Researchers are still investigating exactly how these gaps develop and compound over time.

The nutrient question at scale

Extrapolate the access problem in reverse: if 1.5 billion people globally were ever to use GLP-1 drugs at the same rate as early adopters in the US and Europe, the downstream nutritional burden would be enormous. For now, the more immediate concern is for the millions already on these medications who are eating 30-50% less food than before - and likely absorbing fewer micronutrients as a result.

That is not a reason to avoid GLP-1 medications. The weight loss and cardiometabolic benefits are well-documented. It is a reason to pay deliberate attention to what you are still getting in your diet, and to fill gaps where your intake falls short.

Why the global picture matters for your individual health

Studies like this one shape policy. When a paper in The Lancet establishes that 27% of the world's adults qualify for a treatment, it creates pressure on governments, insurers, and manufacturers to expand access. In the US, this kind of data directly informs coverage decisions - including the recently announced Medicare GLP-1 Bridge program that will cap copays at $50 per month starting July 2026.

It also validates the experience of the millions of people who have struggled with obesity for years and been told it is simply a matter of willpower. The science is clear: a significant fraction of the global population has a biology that makes standard approaches to weight management inadequate on their own.

Tirzepatide vs semaglutide: does it matter which drug you take?

The Lancet study did not compare specific drugs, but other 2026 research does. In the SURMOUNT-5 head-to-head trial, tirzepatide (brand names Mounjaro and Zepbound) produced 20.2% weight loss versus 13.7% for semaglutide (Ozempic and Wegovy) over 72 weeks. Both are GLP-1 receptor agonists; tirzepatide additionally activates GIP receptors, which may explain part of the difference. For clinical eligibility purposes, both drugs use the same BMI-based criteria that the Lancet researchers applied.

Frequently asked questions

Who qualifies for GLP-1 medications according to standard criteria?

Current clinical guidelines qualify adults with a BMI of 30 or above, or a BMI of 27 or above in combination with at least one weight-related condition such as type 2 diabetes, hypertension, or sleep apnea. The Lancet study used these same criteria across its 810,635-person dataset.

Why do women qualify for GLP-1 therapy at slightly higher rates than men?

The Lancet data showed 28.5% of women globally meet eligibility criteria versus a lower rate for men. This likely reflects higher obesity prevalence in women across several regions, particularly in sub-Saharan Africa and parts of the Middle East, where female obesity rates have risen sharply since 2000.

Does qualifying for a GLP-1 medication mean you should take one?

Not necessarily. Eligibility means your BMI and health profile meet the threshold where clinical evidence supports considering GLP-1 therapy. Whether a specific drug makes sense for you depends on your medical history, other medications, cost, and personal goals - a conversation to have with your doctor, not a decision made by a checklist alone.

What nutrients should people on GLP-1 medications monitor?

Early research flags vitamin B12, vitamin D, iron, and magnesium as nutrients most likely to fall short when eating significantly less. If you have been on a GLP-1 medication for more than a few months, ask your doctor about routine blood work to check these levels.